Komori
General Meetings of Shareholders4547KISSEI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Convocation of the 2026 Annual General Meeting of Shareholders

The notice states that the 81st Annual General Meeting of Shareholders will be held and that proposals concerning the disposition of surplus and the election of directors, Audit & Supervisory Board Members and a substitute Audit & Supervisory Board Member will be submitted. There are 12 director candidates, including 3 new candidates and 4 outside candidates.

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (81st fiscal term)
2026
Jun 23
Date and time10:00 a.m.22 days from this disclosure to the meeting
Matters for resolution4 items
  1. Appropriation of surplus

  2. Election of 12 Directors

  3. Election of 1 Audit & Supervisory Board member

  4. Election of 1 substitute Audit & Supervisory Board Member

Shareholder Proposal

No

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee
12Nominees
3New
4Outside
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (81st fiscal term)
Date and time23 June 2026, 10:00 a.m.
Matters for resolutionProposal 1: Appropriation of surplus, Proposal No. 2: Election of 12 Directors, Proposal No. 3: Election of 1 Audit & Supervisory Board member, Proposal No. 4: Election of 1 substitute Audit & Supervisory Board Member
Shareholder ProposalNo
Director nominee12, including 3 new candidates and 4 outside directors
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

All directors and Audit & Supervisory Board Members will reach the end of their terms. With respect to the substitute Audit & Supervisory Board Member, the validity of the election of the substitute Audit & Supervisory Board Member elected at the 2024 general meeting will expire.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2026 Annual General Meeting of Shareholders | KISSEI PHARMACEUTICAL CO.,LTD. (4547) timely disclosure | Komori